

Lebanon

Population 2015

5.9 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.061 (0.038–0.09)	1 (0.65–1.5)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.02 (0–0.06)
Incidence (includes HIV+TB)	0.75 (0.65–0.87)	13 (11–15)
Incidence (HIV+TB only)	<0.01 (<0.01–0.011)	0.15 (0.12–0.19)
Incidence (MDR/RR-TB)**	0.028 (<0.01–0.049)	0.48 (0.12–0.84)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.031 (0.02–0.042)	0.39 (0.32–0.45)	0.42 (0.34–0.49)
Males	0.024 (0.017–0.032)	0.31 (0.24–0.38)	0.34 (0.26–0.41)
Total	0.056 (0.041–0.07)	0.7 (0.64–0.76)	0.75 (0.65–0.87)

TB case notifications, 2015

Total cases notified	666
Total new and relapse	656
- % tested with rapid diagnostics at time of diagnosis	36%
- % with known HIV status	27%
- % pulmonary	60%
- % bacteriologically confirmed among pulmonary	63%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.08 (0.05–0.12)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	4	2%
- on antiretroviral therapy	4	100%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			18 (6–30)
Estimated % of TB cases with MDR/RR-TB	2.6% (0–5.4)	43% (9.9–82)	
% notified tested for rifampicin resistance	35%	56%	235
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 2, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 3, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	76%	671
Previously treated cases, excluding relapse, registered in 2014	80%	10
HIV-positive TB cases, all types, registered in 2014	33%	3
MDR/RR-TB cases started on second-line treatment in 2013	86%	7
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	4%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2016

National TB budget (US\$ millions)	1.8
Funding source: 34% domestic, 66% international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded
Funded internationally
Funded domestically